aestheticmedguideAestheticMedGuide
Skin

Sclerotherapy for spider and leg veins: Asclera, Sotradecol, ultrasound, and laser

Sclerotherapy is the gold standard for spider and leg reticular veins, using FDA-approved sclerosants Asclera and Sotradecol. The evidence, foam vs liquid, Nd:YAG laser, and skin-of-color safety.

Ran Chen
Ran Chen
10 min read · Published · Evidence-based

Spider veins (telangiectasias) and the slightly larger blue reticular veins that feed them are the small, visible vessels that thread through the skin of the legs — and, less often, the face. Most are harmless and treated for cosmetic reasons, but they sit on a spectrum with real vein disease: the same faulty one-way valves that let blood pool and stretch a tiny surface vessel can, in some people, be a sign of underlying venous insufficiency. That distinction — cosmetic spider vein versus a symptom of a deeper refluxing vein — is the single most important thing to get right before any treatment, because injecting the surface vessels of a leg with an untreated varicose vein underneath is wasted effort that will end in recurrence.

The good news is that the cornerstone treatment, sclerotherapy, has been in use since the 1930s, uses FDA-approved injectable sclerosants with well-characterized outcomes, and remains the gold standard for leg spider and reticular veins. The FDA has approved exactly two liquid sclerosants for this purpose — Asclera (polidocanol) and Sotradecol (sodium tetradecyl sulfate) — plus one commercial foam (Varithena). This article covers how sclerotherapy works, when surface laser (the long-pulsed 1064 nm Nd:YAG) is the better tool, why ultrasound matters, and the skin-of-color and safety considerations that decide who is a candidate. It is educational and not a substitute for evaluation by a vein specialist, dermatologist, or vascular clinician.

How sclerotherapy works — and what the FDA approved

Sclerotherapy injects a chemical sclerosant directly into the unwanted vein. The agent damages the vessel's inner lining (endothelium), the vein collapses and scars shut, and over weeks to months the body absorbs it so it fades from view. In the United States, only polidocanol and sodium tetradecyl sulfate are FDA-approved as liquid sclerosants:

  • Asclera (polidocanol) was FDA-approved in March 2010 to treat uncomplicated spider veins (≤1 mm) and uncomplicated reticular veins (1–3 mm) of the lower extremity. The label states it has not been studied in veins larger than 3 mm. In its pivotal trials, patient satisfaction at 12 weeks was 87% with polidocanol versus 64% with sodium tetradecyl sulfate and 14% with placebo.
  • Sotradecol (sodium tetradecyl sulfate, STS) was approved (originally in 1946, re-approved by the generic-drug pathway in 2004) for small, uncomplicated varicose veins of the lower extremity with simple dilation and competent valves.
  • Varithena (polidocanol injectable foam), approved November 2013, is the only FDA-approved foam sclerosant, indicated for incompetence of the great saphenous vein system — a larger, deeper vein than a cosmetic spider vein.

Two cautions from the Asclera label deserve emphasis. First, it carries serious warnings — anaphylaxis (some cases fatal), venous thrombosis and pulmonary embolism, arterial embolism, and tissue ischemia and necrosis — and the label instructs that the provider be prepared to treat anaphylaxis with appropriate emergency equipment on hand. Second, sclerosants are contraindicated in acute thromboembolic disease and known allergy. "It's just a cosmetic injection" understates a drug with a real, if rare, serious-event profile; this is a procedure for a credentialed clinical setting, not a med-spa back room.

Liquid, foam, and ultrasound-guided sclerotherapy

The form the sclerosant takes is matched to vessel size. Liquid sclerotherapy is used for the smallest vessels — telangiectasias and small reticular veins. For larger varicose veins, the sclerosant is mixed with air or gas to create foam, which displaces blood from the vein and maximizes contact with the vessel wall; foam is therefore more effective for bigger, higher-flow vessels. Foam is either physician-compounded at the time of treatment (inconsistent bubble size) or the commercially manufactured Varithena microfoam (consistent, controlled density).

When the target is a deeper or refluxing vein that cannot be seen from the surface, sclerotherapy is performed under ultrasound guidance (ultrasound-guided sclerotherapy, UGS), which lets the clinician deliver sclerosant precisely to the diseased vessel. This is where the line between cosmetic and medical treatment blurs, and where the workup below matters.

The step most often skipped — duplex ultrasound and treating reflux first

The decision that separates a good outcome from a wasted one is made before any injection: is there underlying venous insufficiency? Surface spider veins in a leg with a refluxing saphenous or perforator vein will reappear if the deeper reflux is not addressed first. The correct sequencing, per venous-disease guidelines, is:

  1. Duplex ultrasound (DUS) to map the leg's venous anatomy and identify reflux in the saphenous, perforator, or tributary veins.
  2. Treat the source of reflux first — typically endovenous thermal ablation (laser or radiofrequency), mechanochemical ablation, cyanoacrylate adhesive closure (VenaSeal, PMA-approved 2015), or Varithena foam for the incompetent truncal vein.
  3. Then treat the tributaries and surface spider/reticular veins with sclerotherapy or laser.

A clinic that offers to inject your spider veins without a standing or lying-down ultrasound evaluation is treating the visible tip while ignoring the root. The caveat, well covered in clinical policy documents, is that sclerotherapy of isolated tributary or spider veins without concurrent treatment of saphenous reflux is often deemed not medically necessary — meaning it is cosmetic, cash-pay, and likely to recur.

When laser is the better tool

For most leg spider veins, sclerotherapy remains the gold standard — studies comparing the two on the same patient's legs generally show sclerotherapy clearing vessels better and faster. But surface laser has clear niches:

  • The long-pulsed 1064 nm Nd:YAG is the workhorse laser for leg veins, achieving over 70% clearance after typically 2–3 sessions at 6–8 week intervals for vessels roughly 0.5–3 mm. It is the choice for patients who cannot tolerate needles or sclerosants, for very small vessels below the practical injection threshold, and for stubborn or needle-phobic cases.
  • Facial telangiectasia (around the nose, cheeks) is a laser problem more than a sclerotherapy problem — PDL/Vbeam, KTP (532 nm), and Nd:YAG are the standard tools there, as we detail in our PDL/Vbeam vs. Excel V comparison.
  • Telangiectatic matting — the fine red net that can appear after sclerotherapy — often resolves on its own; persistent matting can be treated with a feeder-vessel injection or a 1064 nm Nd:YAG, PDL, alexandrite, or IPL.

The laser-versus-injection decision is not about which technology is "more advanced"; it is about vessel size, location, and patient factors. Lasers cost more to deliver per session than a needle and syringe, and they carry their own burn and pigmentation risks — the same energy-device safety considerations we cover for skin of color in our skin-of-color protocol.

Skin of color, pigmentation, and recovery

A particular concern in Fitzpatrick IV–VI is post-treatment pigmentation. When a treated vein ruptures or leaks, red blood cells break down and leave hemosiderin (iron pigment) in the skin — a brownish stain that can persist for months and is more visible on darker skin. Lower sclerosant concentrations, avoiding over-aggressive treatment of too many veins in one session, and disciplined use of compression stockings (typically 20–30 mmHg) afterward all reduce this risk, as does sun protection of the treated legs. IPL, with its broad spectrum and melanin absorption, is a poorer choice in darker skin types than a wavelength-selective Nd:YAG. Patients prone to keloids (see our keloid treatment guide) should note that sclerotherapy and surface laser do not involve incisions, so scarring risk is minimal — but any pigmentation that occurs still needs to be weighed against cosmetic benefit.

Recovery is generally quick: sessions take 15–45 minutes, you walk immediately afterward, and compression stockings are worn continuously for the first few days and then during the day for one to three weeks, with the exact duration matched to vessel size (shorter for small spider veins, longer for reticular veins). Set expectations honestly: treated veins often look darker and more prominent before they fade — sometimes called "looking worse before better" — as the vessel seals and is absorbed. Small spider veins typically fade over 3 to 6 weeks, while larger veins can take 3 to 4 months to fully resolve, and a single vein can keep improving for up to six months. Sessions are usually spaced roughly four to six weeks apart, and multiple sessions are the norm rather than the exception.

What it costs and what to expect

Sclerotherapy is usually cosmetic and cash-pay when performed for spider veins without medical symptoms; it is more likely covered when tied to symptomatic venous insufficiency after the ultrasound workup above. Per the American Society of Plastic Surgeons, the average physician's fee is roughly $300–$450 per sclerotherapy session (laser sessions are similar), not counting facility or consultation fees; packages and per-area pricing are common. Realistic expectations: most people need several sessions — typically 1–4 for sclerotherapy — and treated vessels are gone for good, but new ones can form in other locations over years as the underlying tendency to vein disease continues. Maintenance sessions over time are normal.

What to ask a vein specialist or dermatologist

  • Will I get a duplex ultrasound, and why or why not? A credible plan for leg veins addresses underlying reflux, not just the surface.
  • Which FDA-approved sclerosant will you use, and why? Asclera (polidocanol) for spider and reticular veins; Sotradecol and Varithena for larger disease.
  • How many sessions are realistic for my veins, and what's the maintenance plan? Honesty here beats a one-and-done promise.
  • What is my pigmentation risk, and how will you minimize it? Especially relevant for skin of color — ask about concentration, compression, and sun protection.
  • What serious adverse events should I watch for, and how are they handled? Anaphylaxis, DVT/PE, and skin necrosis are label-level risks; ask about emergency readiness.
  • Are you treating me for cosmetic spider veins or for venous disease — and does that change coverage and sequencing? The answer should be explicit.

Spider and reticular veins are among the most treatable concerns in aesthetic medicine — with FDA-approved sclerosants that have decades of use behind them and a well-defined laser alternative. The patients who get durable results are the ones who insist on an ultrasound workup first, who match the tool (liquid, foam, or laser) to the vessel, who manage pigmentation risk honestly in skin of color, and who treat vein care as the staged, maintenance-oriented process it is rather than a single cosmetic fix.

Sources

Topics
Vascular RednessSkin of ColorCostSafety
Ran Chen
Contributing Editor
Ran Chen

Founder, AestheticMedGuide. Life-sciences operator covering aesthetic devices, injectables, and the industry behind them. Previously global market-access lead across pharma and medtech.

Follow on LinkedIn →

Keep reading from Skin

See all →
Skin · 10 min read

Keloid and hypertrophic scar treatment: steroids, 5-FU, laser, and why excision fails

Keloids and hypertrophic scars are raised scars that overgrow the wound. The evidence ladder: intralesional triamcinolone, 5-FU, cryotherapy, PDL,…

Skin · 10 min read

Rosacea treatment: a subtype-by-subtype guide to what actually works

Rosacea is treated by matching therapy to the feature that bothers you — redness, bumps, visible vessels, thickened skin, or eye symptoms. The…

Devices · 8 min read

Laser Hair Removal vs Electrolysis: What's Actually Permanent, and When Each Wins

Electrolysis is FDA-approved for permanent hair removal. Laser is cleared for permanent hair reduction. Here is how mechanisms, candidacy, cost, and…